Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 7, 2009, Pages 821-834

  Tapsall, John W ^b   Ndowa, Francis ^c   Lewis, David A ^d,e   Unemo, Magnus ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c Natl Comm for Contr of AIDS Bur   (Switzerland)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antibiotic resistance; Antibiotics; Cephalosporin; Neisseria gonorrhoeae; Surveillance; WHO

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFDITOREN; CEFIXIME; CEFODIZIME; CEFOTAXIME; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE; THIAMPHENICOL;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENETICS; BACTERIAL MUTATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM TRANSFORMATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GEOGRAPHIC DISTRIBUTION; GONORRHEA; HORIZONTAL GENE TRANSFER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; PUBLIC HEALTH PROBLEM; REVIEW; SEXUAL TRANSMISSION; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE; POPULATION SURVEILLANCE; PREVALENCE; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

EID: 70350627375     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.63     Document Type: Review

References (78)

1. Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment for gonorrhea: some possible remedies. Exp. Rev. Anti Infect. Ther. 4(4), 619-628 (2006). (Pubitemid 44523940)
2. WHO. Global surveillance network for gonococcal antimicrobial susceptibility. WHO/VDT/90-452. WHO, Geneva, Switzerland (1990).
3. Cohen MS, Hoffman IF, Royce RA et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 349, 1868-1873 (1997).
4. Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial- resistant Neisseria gonorrhoeae. Emerg. Infect. Dis. 11(8), 265-273 (2005).
5. WHO. Surveillance standards for antimicrobial resistance. WHO/CDS/CSR/DRS/2001.5 WHO, Geneva, Switzerland (2001).
6. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/ DRS/2001.3 WHO, Geneva, Switzerland (2001).
7. Anonymous. Discontinuation of spectinomycin. MMWR 55, 370 (2006).
8. Tapsall J. Implications of current recommendations for third-generation cephalosporins use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex. Transm. Infect. 85(4), 256-258 (2009).
9. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impeding problem of resistance. Expert Opin. Pharmacother. 10(4), 555-577 (2009).
10. Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment for gonorrhea. Emerg. Infect. Dis. 13(8), 1275-1277 (2007).
11. Lo JYC, Ho KM, Leung AOC et al. Ceftibuten resistance and treatment failure in gonococcal infection. Antimicrob. Agents Chemother. 52(10), 3564-3567 (2008). • Recent publication clearly documenting treatment failure with oral third-generation cephalosporins.
12. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann. Intern. Med. 148(8), 606-613 (2008). • Treatment options and control measures required following the emergence of cephalosporin-resistant gonococci.
13. Deguchi T, Yasuda M. Lack of nationwide surveillance of antimicrobial resistance in Neisseria gonorrhoeae in Japan. Ann. Intern. Med. 149(5), 363-364 (2008).
14. Wang SA, Lee MV, O'Connor N et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime - Hawaii, 2001. Clin. Infect. Dis. 37(6), 849-852 (2003). (Pubitemid 37153668)
15. Tapsall J. Multi-drug resistant Neisseria gonorrhoeae. CMAJ 180(3), 268-269 (2009).
16. Vernel-Paulliac F, Nandi S, Nicholas RA, Goarant C. Genotyping as a tool for antibiotic resistance surveillance in New Caledonia: evidence of a novel genotype associated with reduced penicillin sensitivity. Antimicrob. Agents Chemother. 52(9), 3293-3300 (2008).
17. Vernel-Paulliac F, Hogan TR, Tapsall JW, Goarant C. Quinolone-resistance in Neisseria gonorrhoeae: rapid genotyping of quinolone resistance-determining regions in gyrA and parC genes by melting curve analysis predicts susceptibility. Antimicrob. Agents Chemother. 53(3), 1264-1267 (2009).
18. Tapsall J, Whiley D, Sloots T. Applications of molecular testing in clinical laboratories for the diagnosis and control of gonorrhea. Future Microbiol. 1(3), 317-324 (2006).
19. Shultz TR, Tapsall JW, White PA. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae with changes in GyrA and ParC. Antimicrob. Agents Chemother. 45(3), 734-738 (2001).
20. Unemo M, Palmer HM, Blackmore T et al. Global transmission of prolyliminopeptidase (PIP) - negative Neisseria gonorrhoeae strains - implications for changes in diagnostic strategies? Sex. Transm. Infect. 83(1), 47-51 (2007). (Pubitemid 46293805)
21. Limnios EA, Nguyen N-L, Ray S, McIver CJ, Tapsall JW. Dynamics of appearance and expansion of a prolyliminopeptidase-negative subtype among Neisseria gonorrhoeae isolates collected in Sydney, Australia, from 2002 to 2005. J. Clin. Microbiol. 44, 1400-1404 (2006).
22. Lum G, Freeman K, Nguyen NL et al. A cluster of culture positive gonococcal infections but with false-negative cppB-gene-based PCR. Sex. Transm. Infect. 81(5), 400-402 (2005). (Pubitemid 41494354)
23. Furuya R, Onoye Y, Kanayama A et al. Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. J. Infect. Chemother. 13(5), 302-304 (2007). (Pubitemid 350059919)
24. Tanaka M, Nakayama H, Huruya K et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int. J. Antimicrob. Agents 27(1), 20-26 (2006). (Pubitemid 43042418)
25. Saika T, Nishiyama T, Kanayama A et al. Comparison of Neisseria gonorrhoeae isolates from the genital tract and pharynx of two gonorrhea patients. J. Infect. Chemother. 7(3), 175-179 (2001). (Pubitemid 33043211)
26. Ohnishi M, Watanabe Y, Shimuta K, Watanabe H. Horizontal transfer of penA allele between two different lineages of Neisseria gonorrhoeae. Presented at: 18th International Society for Sexually Transmitted Disease Research Conference. London, UK, 28 June-1 July 2009.
27. Rowbottom JH, Tapsall JW, Plummer DC et al. An outbreak of a penicillin-sensitive strain of Neisseria gonorrhoeae in Sydney men. Genitourin. Med. 70(3), 196-199 (1994).
28. Tapsall JW, Limnios EA, Murphy DM; Australian Gonococcal Surveillance Programme. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia 1997-2006. J. Antimicrob. Chemother. 61(1), 150-155 (2008).
29. Morris SR, Knapp JS, Moore DF et al. Using strain typing to characterise a fluoroquinolone-resistant Neisseria gonorrhoeae transmission network in southern California. Sex. Transm. Infect. 84(4), 290-291 (2008).
30. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin. Infect. Dis. 41(Suppl. 4), S263-S268 (2005).
31. Tapsall JW, Shultz TR, Limnios EA, Donovan B, Lum G, Mulhall BP. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex. Transm. Dis. 25(10), 505-508 (1998). (Pubitemid 28553604)
32. Palmer HM, Young H, Winter A, Dave J. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J. Antimicrob. Chemother. 62(3), 490-494 (2008).
33. WHO Collaborating Centre for STD, Sydney. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. Technical document D007-0408-0401#1 (2008).
34. Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular methods. J. Med. Microbiol. 58(5), 683-687 (2009). •• Documented treatment failure described with ceftriaxone treatment for pharyngeal gonorrhea.
35. Ng L-K, Martin I, Liu G. Bryden L. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46(9), 3020-3025 (2002). (Pubitemid 34898687)
36. Chisholm SA, Ison C. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. Euro Surveill. 13(15), 18832 (2008).
37. th International Society for Sexually Transmitted Disease Research conference. London, UK, 28 June-1 July 2009.
38. Starnino S, Stefanelli P; Neisseria gonorrhoeae Italian Study Group IN. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J. Antimicrob. Chemother. 63(6), 1200-1204 (2009).
39. Annual report of the Australian Gonococcal Surveillance Programme, 2007. Commun. Dis. Intell. 32(2), 227-231 (2008).
40. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2007. Atlanta, GA, USA (2008).
41. Health Protection Agency. GRASP: The Gonococcal Resistance to Antimicrobials Surveillance Programme Annual Report 2007 (2008).
42. Unemo M, Olcén P, Fredlund H et al. Neisseria gonorrhoeae 2008. Annual report regarding serological characterisation and antibiotic susceptibility of Swedish Neisseria gonorrhoeae. National Reference Laboratory for Pathogenic Neisseria, Örebro, Sweden (2009).
43. Lewis DA, Scott L, Slabbert M et al. Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity. Sex. Transm. Infect. 84(5), 352-355 (2008).
44. Kubanova A, Frigo N, Kubanov A et al. National surveillance of antimicrobial susceptibility in Neisseria gonorrhoeae in 2005-2006 and recommendations of first-line antimicrobial drugs for gonorrhoea treatment in Russia. Sex. Transm. Infect. 84(4), 285-289 (2008).
45. Domeika M, Ismailov R, Babayan K et al. Performance of any antimicrobial resistance testing of Neisseria gonorrhoeae in East-European Countries of North Caucasus and Central Asia? Presented at: 18th International Society for Sexually Transmitted Disease Research conference. London, UK, 28 June-1 July 2009.
46. Cao V, Ratsima E, Van TD et al. Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in 2004-2006 in Bangui, Central African Republic; Yaounde, Cameroon; Antananarivo, Madagascar; and Ho Chi Minh Ville and Nha Trang, Vietnam. Sex. Transm. Dis. 35(11), 941-945 (2008).
47. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun. Dis. Intell. 32(1), 48-51 (2008).
48. Ray K, Bala M, Kumarai S, Narain JP. Antimicrobial resistance in Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex. Transm. Dis. 32(3), 178-184 (2005). (Pubitemid 40271271)
49. Martin IM, Hoffmann S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J. Antimicrob. Chemother. 58(3), 587-593 (2006). (Pubitemid 44288123)
50. Choudhury B, Bisley CL, Ghani AC et al. Identification of individuals within sexual networks: a population-based study. Lancet 368, 139-146 (2006). (Pubitemid 43994172)
51. Muratani T, Akasaka S, Kobayashi T et al. Outbreak of cefozopran (penicillin, oral cephems and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob. Agents Chemother. 45(12), 3603-3606 (2001). (Pubitemid 33107887)
52. Muratani T, Inatomi H, Ando Y, Kawai S, Akasaka S, Matsumoto T. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int. J. Urol. 15(9), 837-842 (2008).
53. Bignell C. European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int. J. STD AIDS 20(7), 453-457 (2009).
54. Ameyama S, Onodera S, Takahata M et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46(12), 3744-3749 (2002). • Identification of the role of mosaic penA genes in decreased cephalosporin susceptibility.
55. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob. Agents Chemother. 51(6), 2117-2122 (2007). • Identification of the role of other gene polymorphisms associated with mosaic penA genes in decreased cephalosporin susceptibility.
56. Spratt BG. Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae. Nature 332(6160), 173-176 (1988).
57. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. (2009) (Epub ahead of print). •• Important paper on the differential effects of mosaic PBP2 alleles and other pertinent gene polymorphisms on minimum inhibitory concentrations to ceftriaxone and cefixime.
58. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. Amino acid substitutions of mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 50(11), 3638-3645 (2006). (Pubitemid 44684875)
59. Osaka K, Takakura T, Narukawa K et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J. Infect. Chemother. 14(3), 195-203 (2008). • Role of other mutations in decreasing in vitro susceptibility to ceftriaxone.
60. Ochiai S, Sekiguchi S, Hayashi A et al. Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J. Antimicrob. Chemother. 60(1), 54-60 (2007). (Pubitemid 47073276)
61. Ito M, Deguchi T, Mizutani KS et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob. Agents Chemother. 49(1), 137-143 (2005). (Pubitemid 40065784)
62. Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Further questions regarding the role of mosaic penA sequences in conferring reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 51(2), 802-803 (2007). (Pubitemid 46185313)
63. Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia that are less susceptible to ceftriaxone. Antimicrob. Agents Chemother. 51(9), 3111-3116 (2007). • Describes the broadly based distribution of cephalosporin-resistant gonococcal subtypes and the role of other mutations in decreasing in vitro susceptibility to ceftriaxone.
64. Tapsall JW, Ray S, Lo JYC, Lo ACT, Deguchi T. Distribution of a cephalosporin-resistant sequence type of Neisseria gonorrhoeae with a mosaic PBP2 associated with treatment failure in the Asia-Pacific region. Presented at: 16th International Pathogenic Neisseria Conference, 2008. Rotterdam, The Netherlands, 7-12 September 2008.
65. Wong WW, Huang CT, Li LH, Chiang CC, Chen BD, Li SY. Molecular epidemiological identification of Neisseria gonorrhoeae clonal clusters with distinct susceptibility profiles associated with specific groups at high risk of contracting human immunodeficiency virus and syphilis. J. Clin. Microbiol. 46(12), 3931-3934 (2008).
66. Reyn A, Bentzon MW, Thayer JD, Wilkinson AE. Results of comparative experiments using different methods for determining the sensitivity of Neisseria gonorrhoeae to penicillin G. Bull. WHO 32, 477-502 (1965).
67. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63(6), 1142-1151 (2009). •• Describes the characteristics of a new reference panel of gonococci for use in detection of cephalosporin and other resistance.
68. Bala M, Tapsall JW, Limnios EA, Sood S, Ray K. Experience with an external quality assurance scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae in India, 2001-2007. Epidemiol. Infect. 18, 1-7 (2009).
69. Whiley SM, Bates J, Limnios A, Nissen MD, Tapsall J, Sloots TP. Use of a novel screening PCR indicates presence of Neisseria gonorrhoeae with a mosaic penA gene sequence in Australia. Pathology 39(4), 445-446 (2007). (Pubitemid 47221473)
70. Unemo M, Olcén P, Fredlund H, Thulin S. Real-time PCR and subsequent pyrosequencing for screening of penA mosaic alleles and prediction of reduced susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae. APMIS 116(11), 1004-1008 (2008).
71. Simonsen GS, Tapsall JW, Allegranzi B, Talbot EA, Lazzari S. The antibiotic resistance containment and surveillance approach - a public health approach. Bull. WHO 82, 928-934 (2004). (Pubitemid 40065161)
72. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin. Infect. Dis. 44(Suppl. 3), S84-S101 (2007).
73. Livermore DM, Alexander S, Marsden B et al. Activity of ertapenem against Neisseria gonorrhoeae. J. Antimicrob. Chemother. 54(1), 280-281 (2004). (Pubitemid 39029016)
74. Sutrisna A, Soebjakto O, Wignall FS et al. Increasing resistance to ciprofloxacin and other antibiotics in Neisseria gonorrhoeae from East Java and Papua, Indonesia in 2004 - implications for treatment. Int. J. STD. AIDS. 17(12), 810-812 (2006).
75. Daly CC, Hoffman I, Hobbs M et al. Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. J. Clin. Microbiol. 35(11), 2985-2988 (1997). (Pubitemid 27452451)
76. th International Society for Sexually Transmitted Disease Research Conference. London, UK, 28 June-1 July 2009.
77. Tapsall JW. What management is there for gonorrhea in the post-quinolone era? Sex. Transm. Dis. 33(1), 8-10 (2006).
78. Tapsall J. What is the economic burden imposed by antimicrobial resistance in Neisseria gonorrhoeae? ReACT group (2005) http://react-group.org/ dyn//,10,.html